Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin 14 is a type I keratin and one of the main intermediate filament proteins expressed in the basal layer of the epidermis, where it forms obligatory heterodimers with keratin 5 to provide mechanical strength and resilience to keratinocytes[1][2][3][4]. Mutations in the keratin 14 gene (KRT14) impair filament assembly, leading to skin fragility syndromes such as epidermolysis bullosa simplex[1][2][3]. Keratin 14 is essential for cytoskeletal integrity, influences cell proliferation and differentiation, and plays a key role in maintaining the barrier function and homeostasis of stratified epithelia, such as skin[1][3][4]. K14 may also contribute to the regulation of signaling pathways involved in proliferation and differentiation, including the phosphatidylinositol 3-kinase/Akt and Notch pathways, and indirectly influences cellular responses to mechanical stress[4]. There are currently no known drugs that directly target keratin 14, but its genetic status serves as an important diagnostic marker for inherited blistering diseases[1][2].
Not applicable (no established drugs directly target K14)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin 14 (K14).